We are live on ! Find out more
MNPR icon

Monopar Therapeutics
MNPR

74 hedge funds and large institutions have $361M invested in Monopar Therapeutics in 2025 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 33 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

360% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 5

267% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 9

32% more funds holding

Funds holding: 56 → 74 (+18)

12.43% more ownership

Funds ownership: 70.28% → 82.71% (+12%)

2% more capital invested

Capital invested by funds: $354M → $361M (+$6.5M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
74
Holders Change
+18
Holders Change %
+32.14%
% of All Funds
0.9%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
23
Increased
33
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SL
Siren LLC
Connecticut
+$17.3M
2
SVCM
Saturn V Capital Management
Texas
+$13.9M
3
RCM
RA Capital Management
Massachusetts
+$12.7M
4
PCH
Polar Capital Holdings
United Kingdom
+$8.64M
5
ACM
ADAR1 Capital Management
Texas
+$8.49M

Top Sellers

Rank Fund Capital Flow
1
AAA
Affinity Asset Advisors
New York
-$6.49M
2
ABG
Ally Bridge Group
New York
-$5.26M
3
DCM
Driehaus Capital Management
Illinois
-$2.53M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.61M
5
TCM
TCG Crossover Management
California
-$906K
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
$1.32M +$422K +5,163 +34%
Charles Schwab
27
Charles Schwab
California
$933K +$203K +2,488 +21%
Citigroup
28
Citigroup
New York
$904K +$1.12M +13,689 +9,066%
Renaissance Technologies
29
Renaissance Technologies
New York
$746K +$934K +11,431 New
EI
30
EAM Investors
California
$743K -$266K -3,256 -22%
Squarepoint
31
Squarepoint
New York
$687K +$860K +10,521 New
Goldman Sachs
32
Goldman Sachs
New York
$677K +$313K +3,836 +59%
VF
33
Virtu Financial
New York
$654K +$818K +10,009 New
SEI Investments
34
SEI Investments
Pennsylvania
$452K +$566K +6,926 New
Bank of America
35
Bank of America
North Carolina
$416K +$346K +4,239 +200%
MPIA
36
Mountain Pacific Investment Advisers
Idaho
$398K +$498K +6,100 New
State of Wisconsin Investment Board
37
State of Wisconsin Investment Board
Wisconsin
$376K +$470K +5,757 New
GL
38
Gerber LLC
Ohio
$366K – – –
N
39
Nuveen
North Carolina
$362K +$109K +1,330 +32%
Wells Fargo
40
Wells Fargo
California
$335K +$229K +2,804 +121%
Citadel Advisors
41
Citadel Advisors
Florida
$331K +$414K +5,073 New
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$326K -$24.3K -298 -6%
Two Sigma Investments
43
Two Sigma Investments
New York
$326K +$408K +4,989 New
BNA
44
BankChampaign National Association
Illinois
$295K +$368K +4,510 New
EGM
45
Engineers Gate Manager
New York
$283K +$354K +4,338 New
UBS Group
46
UBS Group
Switzerland
$278K -$304K -3,723 -47%
TI
47
Trexquant Investment
Connecticut
$247K +$309K +3,778 New
VIA
48
Virtus Investment Advisers
Connecticut
$233K +$291K +3,565 New
Deutsche Bank
49
Deutsche Bank
Germany
$220K -$52.2K -639 -16%
Invesco
50
Invesco
Georgia
$219K +$274K +3,355 New
1
2
3 4

MNPR Hedge Fund Activity: Q4 2025 in Review

74 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q4 2025, worth a combined $361M — up 1.8% from $354M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new MNPR positions and 5 closed out — a net gain of 18 holders — while 33 added to existing stakes and 9 trimmed.

The largest buyer was Siren LLC, opening a new position worth an estimated $17.3M. The largest seller was Affinity Asset Advisors, exiting entirely with an estimated $6.49M sold.

  • 74 institutional investors held Monopar Therapeutics (MNPR) as of Q4 2025, up from 56 in Q3 2025.
  • Funds reported $361M of Monopar Therapeutics stock for Q4 2025, up 1.8% quarter-over-quarter.
  • 23 funds opened new Monopar Therapeutics positions in Q4 2025 and 5 closed out, a net change of +18 holders.
  • The largest Monopar Therapeutics buyer in Q4 2025 was Siren LLC, an estimated $17.3M added.
  • The largest Monopar Therapeutics seller in Q4 2025 was Affinity Asset Advisors, an estimated $6.49M sold.

Based on aggregated 13F filings for Q4 2025.